Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune-modulating medications: the masquerading culprit of epididymo-orchitis.

BMJ case reports·2026
Same author

Effect of Heartfulness Meditation on Stress Biomarkers, Burnout and Well-Being: A Randomized Controlled Study.

Stress and health : journal of the International Society for the Investigation of Stress·2025
Same author

Use of single agent Cefotetan for Gustilo-Anderson type III open fracture prophylaxis.

Injury·2023
Same author

Xanthogranulomatous pyelonephritis - A diagnostic and therapeutic dilemma.

The American journal of the medical sciences·2022
Same author

Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2022
Same author

A Risk-Stratified Peri-Operative Protocol for Reducing Surgical Site Infection after Cesarean Delivery.

Surgical infections·2020

Related Experiment Video

Updated: May 11, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
03:23

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Ceftaroline-induced eosinophilic pneumonia.

Kunal R Desai1, Steven D Burdette, Hari M Polenakovik

  • 1Miami Valley Hospital, Wright State University Boonshoft School of Medicine, Dayton, Ohio 45409, USA. desaikunalr@hotmail.com

Pharmacotherapy
|May 8, 2013
PubMed
Summary
This summary is machine-generated.

Ceftaroline, an antibiotic for MRSA infections, can cause eosinophilic pneumonia. Discontinuing the drug and using steroids resolved symptoms, suggesting a drug-induced reaction.

Keywords:
adverse eventceftarolineeosinophilic pneumonia

Related Experiment Videos

Last Updated: May 11, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
03:23

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Ceftaroline is a cephalosporin antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA).
  • MRSA bacteremia can complicate postoperative spinal infections, requiring effective antibiotic therapy.
  • Adverse drug reactions, including pulmonary manifestations, can occur with antibiotic use.

Observation:

  • A patient treated with ceftaroline for MRSA bacteremia developed dyspnea and hypoxemia.
  • Chest imaging revealed diffuse bilateral infiltrates.
  • Peripheral blood eosinophilia and bronchoalveolar lavage fluid with eosinophilic predominance were noted.

Findings:

  • The clinical presentation and laboratory findings were consistent with drug-induced eosinophilic pneumonia.
  • Ceftaroline discontinuation and corticosteroid initiation led to complete resolution of symptoms and radiographic findings.
  • This case highlights a potential adverse effect of ceftaroline therapy.

Implications:

  • Ceftaroline should be considered as a potential cause of drug-induced eosinophilic pneumonia in patients presenting with compatible symptoms.
  • Establishing diagnostic criteria for ceftaroline-induced eosinophilic pneumonia is crucial for timely diagnosis and management.
  • Further investigation into the mechanisms of ceftaroline-induced pulmonary toxicity may inform future drug development and patient monitoring.